Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032-Reference-Cited by-同舟云学术

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Published:2021-01-27 Issue:8 Volume:27 Page:2179-2189
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Yu Alice L.^ORCID,Gilman Andrew L.,Ozkaynak M. Fevzi,Naranjo Arlene,Diccianni Mitchell B.,Gan Jacek,Hank Jacquelyn A.^ORCID,Batova Ayse,London Wendy B.,Tenney Sheena C.^ORCID,Smith Malcolm^ORCID,Shulkin Barry L.^ORCID,Parisi Marguerite,Matthay Katherine K.,Cohn Susan L.^ORCID,Maris John M.^ORCID,Bagatell Rochelle^ORCID,Park Julie R.,Sondel Paul M.

Funder

NIHNCINCI

St. Baldrick's FoundationAlex's Lemonade Stand FoundationPadres FoundationLou Bridgeman Memorial FundAlex's Lemonade Stand FoundationPadres FoundationLou Bridgeman Memorial Fund

NCI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MYCN in neuroblastoma: The kings' new clothes and drugs;EJC Paediatric Oncology;2024-12

2. US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy;Journal of Clinical Oncology;2024-09-01

3. Single-cell profiling of surface glycosphingolipids opens a new dimension for deconvolution of breast cancer intratumoral heterogeneity and phenotypic plasticity;Journal of Lipid Research;2024-09

4. Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma;Cancers;2024-08-17

5. Therapeutic SHPRH-146aa encoded by circ-SHPRH dynamically upregulates P21 to inhibit CDKs in neuroblastoma;Cancer Letters;2024-08